Skip to content
OpenCapital
Get started

Corvus Pharmaceuticals CRVS Net interest and investment income (loss)

Net interest and investment income (loss) at other companies

ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
——

Other financials

Income statement

See full
Operating income-$14.9M-49.9%
Net income-$13.7M-190%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$40.1M+702%
Total debt$834.0K-27.7%
Total equity$240.7M+388%
Total assets$253.2M+326%

Cash flow

See full
Operating cash flow-$10.4M-25.5%
CapEx$91.0K+153%
Free cash flow-$10.5M-26.1%

Valuation

See full
Market cap$1.1B+259%
Enterprise value$1.06B+251%

Returns & leverage

See full
Return on equity-30.5%-12.5pp
Debt / equity0×0.0×
Current ratio19.8×+14.9×

Where this comes from

Reported directly by Corvus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeNet.

The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corvus Pharmaceuticals's net interest and investment income (loss).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Corvus Pharmaceuticals's net interest and investment income (loss)?
Corvus Pharmaceuticals (CRVS) reported net interest and investment income (loss) of $1.78M in Q1 2026.
How has Corvus Pharmaceuticals's net interest and investment income (loss) changed year-over-year?
Corvus Pharmaceuticals's net interest and investment income (loss) increased by 239.8% year-over-year, from $525K to $1.78M.
What is the long-term trend for Corvus Pharmaceuticals's net interest and investment income (loss)?
Over 3 years (2022 to 2025), Corvus Pharmaceuticals's net interest and investment income (loss) has grown at a 56.5% compound annual growth rate (CAGR), from $654K to $2.51M.